VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that it will be ...

Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) announced that it will open its first US brain-dedicated positron emission tomography (PET) scanning clinic at the HCA Florida University Medical ...

The new brand name and visual identity has been designed with a clean and elegant look reflective of the Company’s vision for a streamlined approach to dedicated brain PET imaging, and the ...

The introduction of PET scans that can image more than one radiotracer simultaneously could revolutionize oncology by ...

The Centers for Medicare & Medicaid Services (CMS) has expanded coverage of brain amyloid positron-emission tomography (PET) imaging for the diagnosis of Alzheimer's disease (AD). The CMS decision, ...

Tau proteins play an important role in our normal brain function, mainly by helping to stabilize neurons in the brain. But in Alzheimer’s disease, tau proteins can misfold and tangle inside neurons.

Mass General Brigham researchers used long-term data and a blood test for the biomarker pTau217 to identify the earliest signs of Alzheimer’s disease in cognitively healthy adults.

BUFFALO, N.Y. -- Using positron emission tomography (PET) scanning rather than other types of imaging as the first tool to diagnose heart-vessel blockages is more accurate, less invasive and saves ...

FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.